ZTS — Zoetis Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1555280 ·
Last close
$83.48
Market Cap
$33.92B
52W High
$130.12
52W Low
$68.31
ADV30
4,441,200
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 2,468,000,000 | 1,795,000,000 | 999,000,000 | 691,000,000 | 15,077,000,000 | 1,473,000,000 | 11,929,000,000 |
| Mar 2026 | 2,262,000,000 | 1,621,000,000 | 822,000,000 | 601,000,000 | 15,154,000,000 | 1,940,000,000 | 11,921,000,000 |
| Dec 2025 | 2,387,000,000 | 1,675,000,000 | 826,000,000 | 603,000,000 | 15,467,000,000 | 2,310,000,000 | 12,136,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$2,773,000,000
Investing CF
$-815,000,000
Financing CF
$-2,866,000,000
CapEx
$-495,000,000
Dividends Paid
$-886,000,000
Buybacks
$-3,750,000,000
EPS Diluted TTM
$5.88
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$15,246,000,000
Inventory
$2,536,000,000
Receivables
$1,692,000,000
ST Investments
$200,000,000
EBIT TTM
$3,356,000,000
Pretax Income TTM
$3,114,000,000
Interest Exp TTM
$242,000,000
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$9,493,999,616
EBITDA
$4,032,000,000
Free Cash Flow
$2,053,124,992
Enterprise Value
$39,985,500,160
Total Cash
$1,532,999,936
Total Debt
$9,256,999,936
Shares Out
406,316,147
Trailing EPS
$5.88
Book Value
$8.11
ROE
57.6%
ROA
14.9%
Div Yield
2.67%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 9,467,000,000 | 3,597,000,000 | 2,673,000,000 | 15,467,000,000 | 12,136,000,000 | 3,331,000,000 | 2,904,000,000 |
| Dec 2024 | 9,256,000,000 | 3,392,000,000 | 2,486,000,000 | 14,237,000,000 | 9,467,000,000 | 4,770,000,000 | 2,953,000,000 |
| Dec 2023 | 8,544,000,000 | 3,069,000,000 | 2,344,000,000 | 14,286,000,000 | 9,295,000,000 | 4,997,000,000 | 2,353,000,000 |
| Dec 2022 | 8,080,000,000 | 2,928,000,000 | 2,114,000,000 | 14,925,000,000 | 10,522,000,000 | 4,405,000,000 | 1,912,000,000 |
TTM Snapshot
Revenues TTM
$9,517,000,000
NetIncome TTM
$2,616,000,000
OpCashFlow TTM
—
Assets (Latest)
$15,077,000,000
Forward EPS
$6.40
Max Pain — expiry 2026-12-18
max pain strike: $75.00 · spot: $85.57 · call oi: 9,114 · put oi: 32,652
Expected Move to 2026-12-18:
±$6.49
(7.58%) —
implied range
$79.08 –
$92.06
· ATM straddle on $85.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GMAB | GENMAB A/S | $31.95B | $51.96 | — |
| RPRX | Royalty Pharma plc | $30.58B | $68.68 | — |
| ROIV | Roivant Sciences Ltd. | $28.05B | $38.71 | — |
| INSM | INSMED Inc | $26.73B | $121.86 | — |
| ONC | BeOne Medicines Ltd. | $43.55B | $413.26 | — |
News headlines (Yahoo Finance, 1h cache)
ETFs Are Net Sellers of Zoetis (ZTS) on Monday
2026-11-18 11:03 · Yahoo
GSK vs. Zoetis: Which Dividend Stock Pays You More in 10 Years?
2026-11-13 17:39 · Yahoo
Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch Relief
2026-11-12 13:48 · Yahoo
Zoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic Dermatitis
2026-11-11 12:30 · Yahoo
What Are Wall Street Analysts' Target Price for Zoetis Stock?
2026-11-11 10:52 · Yahoo
Should You Buy Zoetis Stock At This Price?
2026-11-11 00:27 · Yahoo
Zoetis to Participate in the Jefferies Global Healthcare Conference in London
2026-11-10 12:30 · Yahoo
ZTS Q3 2026 deep dive: competitive pressures and margin headwinds weigh on outlook
2026-11-10 09:41 · Yahoo
ZTS Q3 Earnings Call Highlights Competitive Pressures and Outlook
2026-11-09 14:00 · Yahoo
What Zoetis (ZTS) Said on Its Q3 Earnings Call
2026-11-08 22:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.